Regeneron ' s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients

TARRYTOWN, N.Y., Sept. 29, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials